期刊
FUTURE ONCOLOGY
卷 13, 期 14, 页码 1263-1279出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0072
关键词
checkpoint inhibitors; chemotherapy; immunotherapy; Merkel cell carcinoma; metastasis; systematic literature review
类别
资金
- EMD Serono
- BMS
- Merck KGaA, Darmstadt, Germany
- EMD Serono, USA
- Pfizer, Inc.
- Pfizer
Aim: Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with poor prognosis once metastasized. The aim of this study was to conduct a systematic literature review to assess clinical outcomes associated with chemotherapy regimens in metastatic MCC. Materials & methods: Embase (R), MEDLINE (R), MEDLINE (R)-In-Process and CENTRAL were searched for studies published in January 2016. Results & conclusion: Overall, the literature on chemotherapy in patients with metastatic MCC is sparse, with most studies being case series/reports. Across all studies, response rates ranged from 20 to 61%, with higher response rates in first-line setting (53-61%) versus second-line setting (23-45%). Among responders, duration of response was short (<= 8 months) in both first-and second-line settings. There is a need for novel agents that can induce durable responses in metastatic MCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据